Papers
1
Total Citations
9
H-Index
1
About
Xiaojie Liu is a leading researcher in radiation oncology, with a focused expertise in stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). Her most cited work, a 2017 multi-institutional study analyzing the safety of robotic SBRT for HCC patients, has garnered 9 citations and established foundational insights into treatment-related factors. In this pivotal study, Liu investigated 74 patients with Child–Turcotte–Pugh Class A cirrhosis, identifying key variables that influence the safety profile of robotic SBRT—a critical contribution to optimizing radiation delivery for liver cancer. Her research bridges the gap between advanced radiation technology and clinical oncology, providing evidence-based guidelines that help clinicians minimize toxicity while maximizing tumor control. Liu’s work is particularly notable for its practical impact: by clarifying which patient and treatment factors affect safety, she has enabled more personalized and effective SBRT protocols for HCC. Her findings continue to inform clinical decision-making and inspire further investigations into dose fractionation and organ-at-risk sparing. Through her rigorous methodology and translational focus, Liu has become a respected voice in radiation oncology, advancing safer, more precise cancer treatments.
Research Focus
Key Achievements
Top Papers
- 1